Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients.

Abstract

The management of hepatitis C has progressed from interferon-based therapy to oral direct actingantiviral therapy. Deranged lipid levels (total cholesterol, triglyceride) after treatment with interferon-based therapy are well known. There is a paucity of data on changes in lipid profile, glycemic parameters and alteration in quality of life with the newer regimen. This study was designed to assess the changes in lipid profile, glycemic parameters, quality of life in chronic hepatitis C patients with genotype 3 after treatment with sofosbuvir and daclatasvir. The study was a single-centre, prospective study, conducted at tertiary care hospital from January 2017 to December 2017. Fifty patients, who received sofosbuvir (400mg) and daclatasvir (60mg) orally once daily for a period of 12weeks for chronic hepatitis C and genotype 3, were recruited. Total cholesterol levels (166.9 ± 23.8to 192.4 ± 34.5mg/dL, p-value < 0.0001) and low-density cholesterol (LDL) levels (100.9 ± 22.8to 121.6 ± 37.2, p-value < 0.0001) were elevated after the treatment. A significant decrease in median levels of glycated hemoglobin (HbA1c) was observed (5.57% to 5.41%, p-value < 0.002). Quality of life markedly improved in all domains, i.e. physical, physiological, environmental, andsocial relationships according to an abbreviated form of World Health Organization quality of life assessment namedWHOQOL-BREF questionnaire. Treatment was found to be effective with sustained virological response (SVR) achieved in 94% patients. Our study reports a substantial increment in total cholesterol, andlow-density lipoprotein with sofosbuvir and daclatasvir treatment though it achieved SVR in 94% of patients and improved their quality of life.